SGD Pharma plans major plant investment

The SGD Pharma group is to invest more than €20 million to rebuild a glass melting furnace and modernise production at the Sucy-en-Brie site in France. After a 12 year campaign, the furnace will be completely rebuilt, enlarged and elevated to the same level as the site’s second melter. This work, which will require a change to the building’s superstructure, will allow a 10% reduction in energy consumption, as well as a reduced environmental footprint, with a 10% reduction in emissions to the environment.

The production lines will all be modernised with the latest technologies. In addition, the latest inspection and line control equipment will improve the detection of faulty ware. Work is scheduled to begin in summer 2020.

The Sucy-en-Brie factory has been dedicated to producing pharmaceutical bottles since 1917, supplying syrups, droppers, tablets, injectable and infusion bottles to more than 450 customers around the world. Every year, 80,000 tons of Type II and III flint and amber moulded glass bottles are produced.